

In addition, the following references are submitted herewith as Exhibits 1-5, respectively: Elliott, M.J., et al., "Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to Tumor Necrosis Factor α ," *Arthritis & Rheumatism*, 36(12):1681-1690 (1993); Elliott, M.J., et al., "TNF α Blockade in Rheumatoid Arthritis: Rationale, Clinical Outcomes and Mechanisms of Action," *Immunopharmac.*, 17(2):141-145 (1995); Maini, R.N., et al., "Monoclonal Anti-TNF α Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease," *Immunological Reviews*, No. 144:195-223 (1995); Kingsley, G., et al., "Immunotherapy of Rheumatic Diseases-Practice and Prospects," *Immunol. Today*, 12(6):177-179 (1991); and Trentham, D.E., "Immunotherapy and Other Novel Therapies," *Curr. Opin. Rheumatol.*, 3:369-372 (1991).

Please amend the application as follows:

In the Claims:

Please amend Claim 123 and add new Claims 125 and 126 as follows:

H¹ 10 ~~123~~. (Twice Amended) A method of treating TNF- α -mediated disease in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to monoclonal antibody cA2 and said disease is selected from the group consisting of immune and autoimmune pathologies, and inflammatory diseases wherein said inflammatory disease is not septic shock.

H² 12 ~~125~~. A method of treating TNF- α -mediated disease in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric